Chakra P. Chaulagain

610 total citations
46 papers, 319 citations indexed

About

Chakra P. Chaulagain is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Chakra P. Chaulagain has authored 46 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 23 papers in Molecular Biology and 14 papers in Genetics. Recurrent topics in Chakra P. Chaulagain's work include Multiple Myeloma Research and Treatments (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Chakra P. Chaulagain is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Chakra P. Chaulagain collaborates with scholars based in United States, Lebanon and France. Chakra P. Chaulagain's co-authors include Raymond L. Comenzo, Ping Zhou, Faiz Anwer, Xun Ma, Monika Pilichowska, Jason Valent, Maroun Bou Zerdan, John K. Erban, Lakshmanan K. Iyer and Sabine Allam and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Chakra P. Chaulagain

41 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chakra P. Chaulagain United States 10 182 138 107 51 41 46 319
Nikolaos Giannakoulas Greece 10 113 0.6× 184 1.3× 85 0.8× 77 1.5× 19 0.5× 27 323
Xianghua Huang China 10 180 1.0× 67 0.5× 51 0.5× 67 1.3× 23 0.6× 32 309
Liya Ma China 11 107 0.6× 121 0.9× 93 0.9× 65 1.3× 22 0.5× 39 305
Katarina Riesner Germany 10 120 0.7× 134 1.0× 55 0.5× 40 0.8× 24 0.6× 31 357
Cheryl Hirsch‐Ginsberg United States 12 86 0.5× 224 1.6× 97 0.9× 51 1.0× 33 0.8× 21 371
Shifeng Lou China 7 177 1.0× 100 0.7× 60 0.6× 94 1.8× 28 0.7× 27 331
Tomoyuki Sasaki Japan 8 81 0.4× 102 0.7× 108 1.0× 22 0.4× 35 0.9× 16 268
Valentina Bozzoli Italy 8 49 0.3× 85 0.6× 123 1.1× 84 1.6× 36 0.9× 17 345
Tung Wynn United States 11 60 0.3× 119 0.9× 31 0.3× 88 1.7× 47 1.1× 23 306
Thilo Zander Switzerland 10 95 0.5× 61 0.4× 143 1.3× 58 1.1× 112 2.7× 25 308

Countries citing papers authored by Chakra P. Chaulagain

Since Specialization
Citations

This map shows the geographic impact of Chakra P. Chaulagain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chakra P. Chaulagain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chakra P. Chaulagain more than expected).

Fields of papers citing papers by Chakra P. Chaulagain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chakra P. Chaulagain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chakra P. Chaulagain. The network helps show where Chakra P. Chaulagain may publish in the future.

Co-authorship network of co-authors of Chakra P. Chaulagain

This figure shows the co-authorship network connecting the top 25 collaborators of Chakra P. Chaulagain. A scholar is included among the top collaborators of Chakra P. Chaulagain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chakra P. Chaulagain. Chakra P. Chaulagain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Comenzo, Raymond L., et al.. (2024). A Pilot Study Assessing the Accuracy of AI ChatGPT Responses for AL Amyloidosis. European Journal Of Haematology. 114(3). 495–499.
3.
Fu, Chieh‐Lin, et al.. (2024). A Real-World Analysis on Access to Triplet and Quadruplet Therapy in Newly Diagnosed Multiple Myeloma Patients in the United States. Clinical Lymphoma Myeloma & Leukemia. 25(1). e1–e10. 1 indexed citations
4.
5.
Chaulagain, Chakra P., et al.. (2024). How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency. SHILAP Revista de lepidopterología. 16(3). 559–567.
6.
Liang, Hong, et al.. (2023). Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States. Leukemia. 38(2). 435–437. 3 indexed citations
7.
8.
Allam, Sabine, et al.. (2023). Liquid biopsies and minimal residual disease in myeloid malignancies. Frontiers in Oncology. 13. 1164017–1164017. 4 indexed citations
9.
Allam, Sabine, et al.. (2022). Multidisciplinary supportive care in systemic light chain amyloidosis. Blood Research. 57(2). 106–116. 7 indexed citations
10.
Zerdan, Maroun Bou, Jason Valent, Maria Julia Diacovo, Karl S. Theil, & Chakra P. Chaulagain. (2022). Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia). Advances in Hematology. 2022. 1–9. 6 indexed citations
11.
Chaulagain, Chakra P., et al.. (2020). Liver failure due to relapsed myeloma and hepatic iron overload. ecancermedicalscience. 14. 1028–1028. 2 indexed citations
12.
Chaulagain, Chakra P., Leah Elson, Raymond L. Comenzo, et al.. (2020). Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. Clinical Lymphoma Myeloma & Leukemia. 20(3). e137–e143. 7 indexed citations
13.
Sadler, Diego, Chakra P. Chaulagain, Robert J. Cubeddu, et al.. (2020). Practical and cost-effective model to build and sustain a cardio-oncology program. Cardio-Oncology. 6(1). 9–9. 16 indexed citations
14.
Chaulagain, Chakra P., et al.. (2020). How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis). Clinical Lymphoma Myeloma & Leukemia. 20(11). e826–e831. 5 indexed citations
15.
Chaulagain, Chakra P.. (2019). Overwhelming Asplenic Sepsis due to Babesiosis. Turkish Journal of Hematology. 36(4). 284–285. 1 indexed citations
16.
Durer, Ceren, Seren Durer, Sarah Lee, et al.. (2019). Treatment of relapsed multiple myeloma: Evidence-based recommendations. Blood Reviews. 39. 100616–100616. 42 indexed citations
17.
Chaulagain, Chakra P., et al.. (2015). Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab. Hematology/Oncology and Stem Cell Therapy. 9(2). 76–79. 6 indexed citations
18.
Chaulagain, Chakra P., Xun Ma, Parul Doshi, et al.. (2015). Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT).. Journal of Clinical Oncology. 33(15_suppl). 8587–8587. 2 indexed citations
19.
Chaulagain, Chakra P., et al.. (2014). Secondary pulmonary alveolar proteinosis in hematologic malignancies. Hematology/Oncology and Stem Cell Therapy. 7(4). 127–135. 32 indexed citations
20.
Chaulagain, Chakra P. & Raymond L. Comenzo. (2013). New Insights and Modern Treatment of AL Amyloidosis. Current Hematologic Malignancy Reports. 8(4). 291–298. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nikolaos Giannakoulas Breakdown of academic impact, for papers by Xianghua Huang Breakdown of academic impact, for papers by Liya Ma Breakdown of academic impact, for papers by Katarina Riesner Breakdown of academic impact, for papers by Cheryl Hirsch‐Ginsberg Breakdown of academic impact, for papers by Shifeng Lou Breakdown of academic impact, for papers by Tomoyuki Sasaki Breakdown of academic impact, for papers by Valentina Bozzoli Breakdown of academic impact, for papers by Tung Wynn Breakdown of academic impact, for papers by Thilo Zander
Rankless by CCL
2026